December 1, 2020, Vol 324, No. 21, Pages 2131-2222
Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19A Randomized Clinical Trial
Wesley H. Self, MD, MPH; Matthew W. Semler, MD; Lindsay M. Leither, DO; et al.
free access has active quiz has audio
JAMA. 2020;324(21):2165-2176. doi:10.1001/jama.2020.22240
This randomized trial compares the effects of hydroxychloroquine vs placebo on clinical status at 14 days (home, requiring noninvasive or invasive ventilation or extracorporeal membrane oxygenation, hospitalized, died) among adults hospitalized with coronavirus disease 2019 (COVID-19).
Question: Does treatment with hydroxychloroquine improve clinical outcomes of adults hospitalized with coronavirus disease 2019 (COVID-19)?
Findings: In this randomized clinical trial that included 479 hospitalized adults with respiratory symptoms from COVID-19, the distribution of the day 14 clinical status score (measured using a 7-category ordinal scale) was not significantly different for patients randomized to receive hydroxychloroquine compared with placebo (adjusted odds ratio, 1.02).
Meaning: These findings do not support the use of hydroxychloroquine for treatment of COVID-19 among hospitalized adults.